Secondary endpoints
regional failure, DM, TTP
TTP, METASTASIS

Compare patient reported GI symptoms using the EPIC at the end of treatment and 3, 6, 12, 24 and 60 months from the end of treatment.Compare patient reported GU symptoms using the EPIC at the end of treatment and 3, 6, 12, 24 and 60 months from the end of treatment.Compare TTP where progression is defined as the first occurrence of biochemical failure (BF), LF, regional failure (RF), distant metastasis (DM), institution of new unplanned anticancer treatment, or PCSM.Compare freedom from biochemical failure (FFBF) and TTP rates with an alternate PSA ≥ PSA nadir + 2 ng/mL definition of BF.Compare LF, RF, salvage therapy (i.e. institution of new unplanned anticancer treatment), DM, PCSM and OS rates.